Amendments to the Specification:

On the first page following the title, replace the paragraph beginning on line 4 with the following:

The application is a continuation-in-part of ~~claims priority to~~ U.S. patent application Serial No. 09/595,338, filed June 14, 2000, now abandoned, which ~~is a conversion application~~ claims the benefit of U.S. provisional application Serial No. 60/139,313, filed June 15, 1999. Both applications are incorporated by reference herein.

On page 1, replace the paragraph beginning on line 2 with the following:

Cytokines are useful in treating a number of human pathologies, including cancers, viral infections, and inflammation. Typically, cytokine treatment involves administering a single, isolated cytokine, e.g., interferon-alpha (IFN-alpha), interferon-beta (IFN-beta), tissue necrosis factor (TNF), etc. Although some treatment efficacy is achieved, the extent of improvement may be suboptimal, particularly in view of severe side effects which the patient may experience.

On page 6, replace the paragraph beginning on line 5 with the following:

The method of the invention is intended for producing a composition containing a mixture of cytokines for therapeutic uses, and in particular, [[a]] cytokine compositions for use in treating cancer, viral infection, and inflammation, as detailed in section III below.

On page 10, replace the paragraph beginning on line 8 with the following:

After culturing the cells under conditions of PKR overproduction (with or without priming), and with above-normal levels of PKR in the cells, the cells are then treated to induce cytokines. Preferred inducing agents are dsRNA, preferably polyIC (poly r(I):poly r(C)), or viral dsRNA such as Sendai virus RNA, administered for example by viral infection or exposure to killed virus or isolated viral dsDNA. In addition, cytokine induction may be produced or enhanced by adding particular cytokines known to

stimulate cytokine production in certain cells, as set out in Table1.[[.]] The inducing agent is added in an amount effective to induce cytokine production, e.g., effective to obtain stimulated levels of cytokines produced and secreted into the culture medium, e.g., in the concentration range between 5-50 ~~ug/ml~~µg/mL.

On page 16, replace the paragraph beginning on line 19 with the following:

The pEF-FLAG-Bcl-X_L vector (Huang, *et al.*, 1997) ~~in Figure 1A~~ contains a full length cDNA encoding the anti-apoptotic Bcl- X_L protein operably linked to the strong elongation factor 1alpha (EF-1 alpha) promoter. An additional salient feature of the vector is the N-terminal FLAG epitope (Hopp *et al.*, 1988) that was added to the Bcl-X_L protein to facilitate selection of cell lines that express high levels of Bcl-X_L.

On page 17, replace the paragraph beginning on line 2 with the following:

The pcDNA-FLAG-PKR vector ~~in Figure 1B~~ contains cDNA encoding the full-length human PKR molecule (551 amino acids; Meurs, *et al.*, 1990; GenBank Accession No. NM002759) modified by the polymerase chain reaction to include the N terminal FLAG tag (Hopp *et al.*, 1988) encoding the sequence MDYKDDDDK, and inserted into the eukaryotic expression vector pcDNA3 (Invitrogen), such that the FLAG-PKR coding sequence was expressed under the control of the CMV promoter.